Inventor

HETTCHE HELMUT

DE26 patents

⚠️ This page may combine multiple inventors who share the name “HETTCHE HELMUT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

HETTCHE HELMUT

ASTA MEDICA AG

Use of R-(+)-α-lipoic acid, R-(-)dihydrolipoic acid and metabolites in the form of the free acid or salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae

Compressed-gas packages using polyoxyethylene glyceryl fatty-acid esters as suspension stabilizers and valve lubricants

Tablets with thioctic acid of specific particle size

Tablets, granulates and pellets with a high active substance content for highly concentrated, solid dosage forms

Compressed gas packages using polyoxyethylene glyceryl oleates

Tablets, granulates and pellets with a high active substance content for highly concentrated, solid dosage forms of thioctic acid

Use of R-(+)-α-lipoic acid, R-(-)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as its sequelae

Use of R-(+)-α-lipoic acid, R-(-)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae

Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability

Use of R-(+)-α-lipoic acid, R-(−)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae

Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability

ASTA PHARMA AG

Controlled release azelastine-containing pharmaceutical compositions

Azelastine containing medicaments

Pharmaceutical composition containing R-α-lipoic acid or S-α-lipoic acid as active ingredient

Pharmaceutical compositions containing R-α-lipoic acid or S-α-lipoic acid as active ingredient

Method of treating inflammatory diseases with pharmaceutical composition containing dihydrolipoic acid as active substance

Method of treating inflammatory disorders and psoriasis with salts of azelastine

Salts of azelastine having improved solubility effective at treating psoriasis and providing a cytoprotective effect

Salts of azelastine having improved solubility

Salts of azelastine having improved solubility useful at providing a cytoprotective effect

Synergistic combination of azelastine and theophylline or azelastine and α-mimetics

DEGUSSA

Synergistic combination of amantadiene and selegiline

Combination of flupirtin and anticholinergic acting spasmolytic

2-amino-3-ethoxycarbonylamino-6-(p-fluoro-benzylamino)-pyridine gluconate and pharmaceutical preparations containing it

VIATRIS GMBH

Oral forms of administration containing solid flupirtine with controlled release of active substance

TIBES ULRICH

Synergistic combination of flupirtin and non-steroidal antiphlogistic